Nectar Lifesciences Limited Stock

Equities

NECLIFE

INE023H01027

Pharmaceuticals

Delayed NSE India S.E. 09:03:23 2024-04-25 am EDT 5-day change 1st Jan Change
34.25 INR -1.01% Intraday chart for Nectar Lifesciences Limited +3.32% +6.53%
Sales 2022 16.69B 200M Sales 2023 15.24B 183M Capitalization 3.58B 42.95M
Net income 2022 250M 3M Net income 2023 -242M -2.91M EV / Sales 2022 0.83 x
Net Debt 2022 8.42B 101M Net Debt 2023 7.36B 88.37M EV / Sales 2023 0.72 x
P/E ratio 2022
21.5 x
P/E ratio 2023
-14.8 x
Employees 1,589
Yield 2022 *
-
Yield 2023
-
Free-Float 42.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.01%
1 week+3.32%
Current month+13.60%
1 month+8.90%
3 months-5.12%
6 months+54.28%
Current year+6.53%
More quotes
1 week
33.55
Extreme 33.55
35.90
1 month
30.05
Extreme 30.05
38.80
Current year
29.50
Extreme 29.5
45.70
1 year
16.50
Extreme 16.5
45.70
3 years
14.50
Extreme 14.5
47.90
5 years
7.10
Extreme 7.1
47.90
10 years
7.10
Extreme 7.1
60.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 03-12-31
Founder 64 95-06-26
Director of Finance/CFO 66 22-11-13
Members of the board TitleAgeSince
Founder 64 95-06-26
Director/Board Member 74 10-08-10
Director/Board Member 53 19-02-10
More insiders
Date Price Change Volume
24-04-25 34.25 -1.01% 182,158
24-04-24 34.6 +1.76% 387,965
24-04-23 34 -0.73% 157,876
24-04-22 34.25 +2.85% 291,903
24-04-19 33.3 +0.45% 172,310

Delayed Quote NSE India S.E., April 25, 2024 at 09:03 am EDT

More quotes
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
More about the company
  1. Stock Market
  2. Equities
  3. NECLIFE Stock